scholarly journals The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis

2018 ◽  
Vol 15 (4) ◽  
pp. 239-248 ◽  
Author(s):  
DIPANJAN BASU ◽  
CLÁUDIA M. SALGADO ◽  
BRUCE BAUER ◽  
YASMIN KHAKOO ◽  
JANKI R. PATEL ◽  
...  
2016 ◽  
Vol 04 (01) ◽  
pp. 4-10

AbstractImmunosuppression permits graft survival after transplantation and consequently a longer and better life. On the other hand, it increases the risk of infection, for instance with cytomegalovirus (CMV). However, the various available immunosuppressive therapies differ in this regard. One of the first clinical trials using de novo everolimus after kidney transplantation [1] already revealed a considerably lower incidence of CMV infection in the everolimus arms than in the mycophenolate mofetil (MMF) arm. This result was repeatedly confirmed in later studies [2–4]. Everolimus is now considered a substance with antiviral properties. This article is based on the expert meeting “Posttransplant CMV infection and the role of immunosuppression”. The expert panel called for a paradigm shift: In a CMV prevention strategy the targeted selection of the immunosuppressive therapy is also a key element. For patients with elevated risk of CMV, mTOR inhibitor-based immunosuppression is advantageous as it is associated with a significantly lower incidence of CMV events.


PEDIATRICS ◽  
2000 ◽  
Vol 106 (4) ◽  
pp. 736-741 ◽  
Author(s):  
F. V. Bittencourt ◽  
A. A. Marghoob ◽  
A. W. Kopf ◽  
K. L. Koenig ◽  
R. S. Bart

Diabetes ◽  
1990 ◽  
Vol 39 (8) ◽  
pp. 924-927 ◽  
Author(s):  
D. L. Gorden ◽  
A. Robert ◽  
V. Y. Moncada ◽  
S. I. Taylor ◽  
J. Muhlhauser ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document